Immunocore Hldgs Q4 GAAP EPS $(0.40) Misses $(0.28) Estimate, Sales $67.59M Beat $67.23M Estimate
Portfolio Pulse from Benzinga Newsdesk
Immunocore Holdings reported Q4 GAAP EPS of $(0.40), missing the $(0.28) estimate, but sales of $67.59M exceeded the $67.23M forecast. This represents a 36.51% decrease in losses and a 34.05% increase in sales compared to the same period last year.
February 28, 2024 | 12:38 pm
News sentiment analysis
Sort by:
Ascending
NEUTRAL IMPACT
Immunocore Holdings reported a larger than expected Q4 loss per share but exceeded sales estimates, showing significant year-over-year improvement in both metrics.
While the EPS miss might concern some investors, the beat on sales and significant year-over-year improvements in both losses and sales could be seen as positive indicators of the company's growth trajectory. The mixed results make the short-term stock price direction uncertain, hence a neutral score.
CONFIDENCE 85
IMPORTANCE 90
RELEVANCE 100